Roles of LOX-1 in microvascular dysfunction.

Area of Science:

• Cardiovascular Biology
• Oxidative Stress Research
• Vascular Medicine

Background:

• Metabolic disease and hypertension cause microvascular damage, including reduced lumen size and density, impairing tissue perfusion and leading to organ damage.
• Oxidative stress, particularly the up-regulation of lectin-like oxidized low density lipoprotein receptor-1 (LOX-1), is strongly associated with these vascular impairments.
• LOX-1 activation leads to endothelial dysfunction, reduced vasodilation, and increased inflammatory markers like IL-6, contributing to microvascular inflammation.

Purpose of the Study:

• To investigate the role of LOX-1 in microvascular dysfunction associated with metabolic diseases and hypertension.
• To explore the relationship between LOX-1, oxidative stress, and inflammatory markers in microvascular endothelial cells.
• To evaluate LOX-1 as a potential therapeutic target for atherosclerotic and microvascular disorders.

Main Methods:

• Analysis of human and animal models with metabolic disease and hypertension.
• Assessment of microvessel structure, including lumen size, wall thickness, and density.
• Evaluation of LOX-1 expression and its correlation with oxidative stress markers, cytokines (IL-6), and endothelial function (NO-dependent vasodilation).

Main Results:

• Metabolic diseases and hypertension are linked to atrophic microvessel remodeling and reduced density.
• LOX-1 up-regulation is a key feature, induced by factors like oxidized LDL (oxLDL).
• LOX-1 activation promotes endothelial dysfunction, inflammation (IL-6 increase), and reactive oxygen species (ROS) generation, while low oxLDL concentrations can promote capillary formation via LOX-1.

Conclusions:

• LOX-1 is a central mediator of endothelial dysfunction and microvascular inflammation in metabolic diseases and hypertension.
• The up-regulation of LOX-1 is closely linked to oxidative stress and inflammatory responses within microvascular endothelial cells.
• Targeting LOX-1 presents a promising therapeutic strategy for treating atherosclerotic diseases and associated microvascular disorders.